Skip to NavigationSkip to content

Mylan reaches agreement with Aspen for their European thrombosis business

Published on 08/09/20 at 12:25pm
Photo by Danny S.

Mylan has announced an agreement to acquire the intellectual property and commercialisation rights to Aspen’s thrombosis business for €641.9 million. 

This includes an upfront payment of €263.2 million and Mylan expects to pay the remainder of the deal from profits generated from their operations by 25 June 2021. 

Mylan President Rajiv Malik commented on the deal: "The acquisition of this thrombosis portfolio is a significant addition to Mylan's European business that will not only make Mylan the second largest supplier of these products to patients in Europe, according to IQVIA, but also bolster our existing commercial infrastructure to further expand access to complex injectables. 

“By adding to our highly experienced sales and marketing team, we will further strengthen our current reach in hospitals and enhance the future growth of our biosimilars franchise in Europe."

Aspen will still manufacture and supply Mylan with the product via their supply chain that is primarily located in Europe. 

The portfolio of products acquired in the deal includes Arixtra, Fraxiparine, Mono-Embolix and Orgaran. Over the last year, this portfolio has generated €231 million in revenue. 

Robert J Coury, Mylan’s Executive Chairman, said: “As we continue toward the launch of Viatris, we remain committed to executing on opportunities that will not only add to Mylan's growth, but that also will be consistent with our vision for Viatris under the Global Healthcare Gateway, which we believe will establish the new company as a true partner of choice.”

Conor Kavanagh

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches